In AIS with inadequate response to tenecteplase, tirofiban vs. placebo increased excellent functional outcome rate at 90 d

The authors investigate whether the addition of tirofiban, compared to placebo, can improve functional outcomes in patients with acute ischemic stroke (AIS) who show inadequate response to tenecteplase. Their findings suggest that tirofiban significantly increases the rate of excellent functional outcomes at 90 days post-treatment.